Cationic amphiphilic drugs (CADs) are small molecules that can induce phospholipidosis (PLD), causing the intracellular accumulation of phospholipid in the lamellar bodies. Nanotechnology based drug delivery systems have been used widely, while it is unknown if drug-induced PLD (DIP) can be potentiated through drug retention by indigestible nanocarriers. Due to the high drug loading capacity of graphene, we investigated if PEGylated graphene oxide (PEG-GO) loaded with CAD could potentiate DIP. Tamoxifen induced the accumulation of NBD-PE, a fluorescence labeled phospholipid in human hepatoma HepG2 cells, while PEG-GO loaded with tamoxifen (PEG-GO/tamoxifen) further potentiated PLD. PEG-GO/tamoxifen induced more gene expression of PLD marker than tamoxifen alone. PEG-GO enhanced DIP was also observed for other CAD, indicating that nanocarrier potentiated DIP could be universal. More lamellar bodies were observed in PEG-GO/tamoxifen treated cells than tamoxifen alone by transmission electron microscopy. When compared with tamoxifen alone, PEG-GO/ tamoxifen showed a delayed but potent PLD. In addition, the retarded PLD recovery by PEG-GO/tamoxifen indicated that the reversibility of DIP was interfered. Confocal microscopy revealed the increased number of lysosomes, greater expression of lysosomal associated membrane protein 2 (LAMP2) (a PLD marker), and an increase in the co-localization between lysosome/LAMP2 and NBD-PE by PEG-GO/tamoxifen rather than tamoxifen alone. Finally, we found that PEG-GO or/and tamoxifen-induced PLD seemed to have no correlation with autophagy. This research suggests pharmaceutical companies and regulatory agencies that if nanoparticles are used as the vectors for drug delivery, the adverse drug effects may be further potentiated probably through the long-term accumulation of nanocarriers.
Nanotechnology based drug delivery systems has a great potential in the arena of cancer diagnostics and treatment. Although small molecules have gained success with approval by the regulatory agencies, their adverse effects and organ toxicity prevents their applications for long-term treatments. To overcome the problems associated with the lack of specificity, poor solubility, low stability, low bioavailability, and drug resistance, small molecules can be loaded on/in nanoparticles (NPs), resulting in an improvement for therapeutic efficacy and efficiency (Ahmed and Aljaeid, 2016; Cheng and Liu, 2016; Kalepu and Nekkanti, 2016; Wang et al., 2010) . Recently, engineered NP including carbon nanotubes, graphene, and a wide range of metal NP were investigated for their drug delivery studies. However, the risk of engineered NP for drug delivery is unpredictable and their biochemical activities along with long-term accumulation in vivo could jeopardize human health. For example, carbon nanotubes were used for drug delivery research, but they have encountered numerous problems due to their intracellular accumulation, leading to oxidative stress, inflammation, and lung fibrosis (Williams and Halappanavar, 2015) . Free metal ions can be released from iron oxide NP or silver NP, causing an elevated intracellular metal ion level, generation of reactive oxygen species, and eventually DNA damage and micronucleus formation (Dos Santos et al., 2014; Valdiglesias et al., 2016) . In comparison, gold NP are relatively inert and therefore have become an attractive delivery system for drug transport and release likely attributed from their unique physicochemical properties (Ghosh et al., 2008) . However, they tend to be retained in the lysosome for 3 weeks in kidney cells, hepatocytes, and dendritic cells associated with an immune response (Tlotleng et al., 2016; Zhou et al., 2016) . Therefore, the intracellular accumulation of nanocarriers within cells is inevitable and safety issues might arise from their physicochemical properties. Second, the slow release of drugs from nanocarriers indicates the slow elimination rate of the drugs. Although nanocarriers have been widely investigated for drug delivery, there are no published data on whether small molecules can further potentiate their adverse effects due to the accumulation of the drugs by the nanocarriers over time in the body.
Adverse effects brought from small molecule drugs vary and depend upon the characteristics of the drugs. Phospholipidosis (PLD) is a type of adverse drug effect with an excessive phospholipid accumulation in the lamellar bodies, a subclass of lysosomes (Reasor, 1989) . Niemann-Pick disease is a genetic condition associated with an abnormal accumulation of sphingomyelin in vivo (McGovern et al., 2006) . Other than genetic diseases, there are many commonly used drugs that can develop PLD in tissues. During the past 40 years, there have been more than 50 cationic amphiphilic drugs (CADs) in the market that can induce PLD. CAD, characterized by a hydrophobic ring structure and a hydrophilic side chain with an amine group that is positively charged at the physiological pH, can be protonated and confined in the acidic lysosomes, introducing drug accumulation accompanied with an abnormal lipid storage (Halliwell, 1997; Lü llmann et al., 1978; Reasor and Kacew, 2001) . National Institutes of Health has investigated the screening for drug-induced PLD (DIP) and found dozens of novel PLD inducers in a library of pharmacologically active compounds, indicating that newly developed compounds may also induce PLD with an unknown risk (Shahane et al., 2014; Sun et al., 2012) . It was hypothesized that CAD may induce PLD through the direct interaction with phospholipases, or forming undigestible complexes via binding onto phospholipids (Gr€ abner, 1987; Hostetler and Matsuzawa, 1981) . However, the detailed mechanisms for DIP have not been elucidated yet.
Some of the CAD can induce toxicity in vivo that may be associated with the presence of PLD. Amiodarone, commonly used for the treatment of arrhythmia, can induce pulmonary toxicity in rats which may be linked to DIP (Reasor, 1989) . Amiodarone has been reported to induce PLD in a large percentage of patients (Atiq et al., 2009) . It caused liver cirrhosis probably attributed from PLD-induced lysosomal swelling, which further introduced the leakage of proteolytic enzymes (Hussain et al., 2013) . Gentamycin, an antibiotic for the treatment of bacterial infections, may cause renal tubular toxicity that is usually accompanied with drug accumulation and PLD (Laurent et al., 1990) . Although it remains as a topic of debate as to whether CAD exert significant toxicological effects on major organs, the U.S. Food and Drug Administration (FDA) looks at it as an adverse effect if PLD occurs in the injured organs, and usually requests that the pharmaceutical companies conduct extra toxicity studies and submit the additional information for review (Berridge et al., 2007; Bhandari et al., 2008; Orogo et al., 2012; Reasor and Kacew, 2001) .
To increase the target specificity of CAD, nanotechnology based drug delivery systems were applied and numerous studies have been conducted. For example, tamoxifen, a marketed drug for breast cancer therapy was loaded on magnetic NP, poly (lactic-co-glycolic acid) NP and solid lipid NP, all of which have shown efficient drug delivery for cancer cells (Kuo and Wang, 2016; Majd et al., 2013; Maji et al., 2014) . However, safety concerns may not be ruled out if these nanocarriers tend to accumulate in normal cells, in which the nanocarriers can retard the small molecules from release. If the small molecule drugs have been known to have some adverse effects (such as PLD), there is a possibility that the nanocarrier may accumulate in the cells and potentiate drug-induced side effects. The biological effects and risk assessment of graphene oxide (GO) nanosheets have been widely explored by different groups through the study of GO interaction with biological systems (Bussy et al., 2015; Kostarelos and Novoselov, 2014; Li et al., 2012; Rauti et al., 2016) . In this study, PEGylated GO (PEG-GO) was used as a nanocarrier model due to numerous reports for its application for therapeutic agent delivery with minimal toxicity after surface modifications Sun et al, 2012; Tian et al., 2016; Xu et al., 2015; Zhang et al., 2014) . We functionalized GO with a PEG coating, which can improve the stability of GO in physiological environments . The high drug loading capacity and minimal toxicity of PEG-GO makes it an attractive nanocarrier model. However, whether the nanocarrier loaded with CAD can potentiate DIP has not been proposed or investigated previously. The physicochemical characteristics of NP and CAD could affect their interaction with lysosomes and their adverse effects of PLD, which further influence the kinetics, efficacy, and toxicity of the drugs. Using a PLD in vitro model along with mechanistic studies, we compared CAD loaded PEG-GO with CAD treatment alone, to investigate if nanocarrier for drug loading can exacerbate adverse drug effects.
MATERIALS AND METHODS
Cells, reagents, and kits. Raw264.7 and human hepatoma HepG2 cells were purchased from Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. 3-Methyladenine (3-MA), paraformaldehyde powder, dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT), tamoxifen, amiodarone, ketoconazole, amitriptyline, chlorpromazine, and fluoxetine were purchased from Sigma-Adrich (St Louis, Missouri). Dulbecco's modified eagle medium (DMEM), N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2 -dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (NBD-PE), Hoechst33258, pentahydrate (bisBenzimide)-FluoroPure Grade, fetal bovine serum (FBS), F(ab') 2 -goat anti-mouse IgG (H þ L) secondary antibody, goat antirabbit IgG (H þ L) secondary antibody, and Alexa Fluor 488/568 conjugate were purchased from Thermo Fisher Scientific (Waltham, Massachusetts). Antibodies including anti-LC3-II (Cell Signaling Technology, Boston, Massachusetts) and antilysosomal associated membrane protein 2 (LAMP-2) (Abcam, Cambridge, England), HRP-labeled goat anti-mouse IgG (H þ L) (Beyotime, China), and HRP-labeled goat anti-rabbit IgG (H þ L) (Beyotime, China) were purchased as indicated. RNAiso Plus, PrimeScript RT reagent kit, and SYBR qPCR premix Ex Taq were purchased from Takara (Dalian, China). Penicillin streptomycin solution (100Â) and phosphate buffered saline were purchased from Solarbio (Beijing, China).
PEG-GO preparation. GO was made by a modified Hummers method . Briefly, expandable graphite flakes (Graftech, Parma, Ohio) were ground with of sodium chloride crystals for 2 days. The remaining ground graphite flakes were dried and stirred in sulfuric acid for 8 h. After the process of acidification, potassium permanganate as an oxidizing agent was slowly added while keeping the temperature <20 C. The mixture was stirred at 35 C for 30 min and 70 C for 45 min.
Next, water was added and the mixture was maintained above 100 C for 15 min. The reaction was terminated by the addition of distilled water and 10 ml of H 2 O 2 solution. The mixture was first washed with hydrochloric acid aqueous solution and then distilled water by repeated centrifugation. Finally, distilled water was added to the pellet and sonicated to make a uniform suspension for storage. To functionalize GO, the obtained GO sheets were covalently functionalized with biocompatible amine terminated polyethylene glycol (PEG, mPEG-NH 2 , 5 kDa) to render them with high aqueous solubility and stability in physiological solutions (Yang et al., 2013) . In brief, 50 mg of mPEG-NH 2 was dissolved in 1mL of deionized water was added into 5 mL of GO solution at pH 7.4 under sonication for 5 min. N-(3-dimethylaminopropyl-N-ethylcarbodiimide) hydrochloride (Sigma-Aldrich, St Louis, Missouri)dissolved in 1 ml of deionized water, and then sonicated for 30 min. PEG-GO were purified by filtration through 100 kDa molecular weight cut-off Amicon filters to remove free PEG and stored under 4 C.
Determination of PEG-GO loading efficiency and capacity. Six CAD including tamoxifen, amiodarone, ketoconazole, amitriptyline, chlorpromazine and fluoxetine (Sigma-Aldrich, St Louis, Missouri) were loaded onto PEG-GO respectively through mixing with PEG-GO and stirred for 12 h under room temperature. Unbound drugs were removed by centrifuge filtration using 100 kDa MWCO filters. Unbound drugs were quantified by ultraviolet-visible spectroscopy (UV-vis)-NIR to determine the drug loading efficiency and capacity of PEG-GO. The formulas were expressed as the following:
Cell viability. Cells viability treated with CAD or PEG-GO was determined using the MTT assay. HepG2 and Raw264.7 cells were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin/streptomycin and incubated at 37 C with 5% CO 2 . Cells were dispensed at 8 Â 10 3 and 25 Â 10 3 cells/well in 96-well plates overnight and treated with drugs or PEG-GO for 24 h. MTT was added and incubated for 4 h at 37 C. The supernatants were removed and the purple formazan crystals were solubilized by DMSO for detection with absorbance at 570 nm in a plate reader (BioTek, Winooski, Vermont). The cell metabolic activity was expressed as the percentage of absorbance between treated groups and untreated control.
PLD assay and high content imaging. NBD-PE contains a fluorophore on the head group of the phospholipid and therefore can be used to quantify the lipid accumulation (PLD) in cells. HepG2 at 25 k/96 well and Raw264.7 at 8 k/96 well were incubated at 37 C overnight. CAD at 2, 4, 8, 16 lM containing 0.5% DMSO were mixed with 25 lg/ml PEG-GO and vortexed overnight at RT. DMSO at 0.5% was used as a negative control. The assay plates were incubated at 37 C for 48 h, fixed with 4% paraformaldehyde solution, stained with Hoechst33258 and rinsed with PBS. The fluorescence images (ex463 nm/em536 nm for NBD-PE; ex352 nm/em461 nm for Hoechst33258) were taken on an ImageXpress Micro Widefield High Content Screening System (Molecular Devices, USA) with a 20Â Plan Fluor objective. Images were acquired with 4 images per well and total 6 wells per sample. Using the MetaXpresss software (Molecular Devices), the green fluorescence were selected from each image and quantified for total fluorescence intensity in the cells, which was further divided by the total number of cell nuclei stained by Hoechst dye (W2 Stained Integrated Intensity/total cells).
Real-time PCR analysis. HepG2 cells were seeded in 6-well plates at a density of 2 Â 10 6 cells per well overnight, and treated for 24 h with tamoxifen alone or PEG-GO/tamoxifen. All primers (SangonBiotech, Shanghai, China) were synthesized as previously described in Sawada et al. (2005) . The total RNA was extracted from collected cells using RNAiso Plus extraction method (TaKaRa, Dalian, China). The concentration of RNA was determined on BiodropmLite (Biochrom, England). Real time PCR was performed using a PrimerScript RT reagent kit (Takara, Dalian, China) according to the manufacturer's instructions. Transcribed cDNA was stored at À20 C until use and real-time PCR was performed on a VIIA7 RT-PCR instrument (Thermo Fisher Scientific, USA). Relative gene expression levels were normalized to the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and calculated using the comparative Ct value by the VIIA7 system software.
Transmission electron microscopy. HepG2 cells were seeded in 100 mm dish, treated with tamoxifen (8 lM) loaded PEG-GO (25 lg/ ml) (PEG-GO/tamoxifen) for 48 h. Following incubation, cells were harvested and washed with PBS. Fixation was conducted in Trump's fixative overnight at 4 C, rinsed with 0.1 M phosphate buffer and then post-fixed with 1% osmium tetroxide (1:1 V/V with 2% osmium stock: 0.2 M phosphate buffer) for 1 h. The samples were rinsed in distilled water twice for 10 min, followed by centrifugation at 800 rpm for 5 min. The supernatant was removed and cells were re-suspended in 3% low melting point agarose at 70 C. Quickly centrifuge the cells in 1.5 ml Eppendorf tube at 10 000 rpm for 1min and cool them down at 4 C for 30 min. Cut black stained cells in the agarose into 5 ml tube, and dehydrate with 50, 70, 95, and 100% ethanol for 15 min, respectively. The cells were further dehydrated with 100% acetone for 10 min for 3 times. The cells were infiltrated with 50% spur (1:1, spur: acetone) for 30 min, followed by 100% spur (Polysciences, Inc., Warrington, Pennsylvania) infiltration for 3 times and overnight. Finally he samples were embedded in fresh spur for polymerization in 70 C for 24 h. Plastic sections were cut at a 1 mm and then stained with azure blue and toluidine blue. Thin sections of 80 nm were cut using an ultramicrotome (Leica EM UC7, Wetzlar, Germany), stained with lead citrate and uranyl acetate, and then placed on 200 mesh copper grids and imaged on a Tecnai G2 Spirit BioTWIN TEM FEI, USA operating at an accelerating voltage of 80 kV.
Western blot analysis. HepG2 cells were treated with tamoxifen alone or PEG-GO/tamoxifen for 48 h. Cells were harvested to extract the protein, and the concentration of the protein was determined using a BCA protein assay kit (Beyotime, Shanghai, China). Protein samples at 30 lg were separated using SDS-PAGE, transferred to a nitrocellulose membrane (BIO-RAD instruments, USA) that was incubated with milk for 1 h at room temperature followed by overnight incubation at 4 Cwith antibodies to LC3
(1:1000) or LAMP2 (1:1000). After washing 3 times with TBS/ Tween-20 buffer, the membrane was incubated with HRP secondary antibodies (1:5000) for 1 h. The immune complexes were visualized with an enhanced chemiluminescence detection system (Thermo Fisher Scientific, Waltham, Massachusetts).
Kinetics and recovery for DIP. To investigate the reversibility of PLD induced by CAD/PEG-GO, the kinetics for intracellular NBD-PE fluorescence was monitored. HepG2 cells were treated with tamoxifen alone or PEG-GO with tamoxifen, the cells were collected through trypsinization at 6 and 48 h, followed by flow cytometry. To study the recovery of PLD when the nanocarrier and drugs were removed, the cells were incubated with tamoxifen or PEG-GO with/tamoxifen for 48 h and then washed and replaced with fresh DMEM medium and stained with the Hoechst dye. The plate was immediately placed in the automatic moving stage for live cell imaging in the high content screening system at 37 C in a humidified atmosphere.
Intracellular NBD-PE and Hoechst were taken with a 20Â objective and 4 sites were selected in each well for recording at an interval of 6 h for 48 h. Images were analyzed with the MetaXpress software according to section 2.4 and the fluorescence of per cell was calculated.
Immunofluorecence staining and confocal imaging. HepG2 cells were seeded onto cover slips in 24-well platesand treated with tamoxifen or PEG-GO/tamoxifen for 48 h. Cells were fixed with 4% paraformaldehyde, rinsed with PBS, permeabilized and blocked by normal goat serum. Primary antibodies for LC3 and LAMP2 were incubated with cells followed by Alexa Fluor goat anti-rabbit/mouse secondary antibodies (Thermo Scientific). Cells were washed with PBS and slides were mounted with antifade reagent (Beyotime). Samples were observed and imaged on an Olympus FV1000 inverted microscope with FV10-ASW software.
RESULTS
Characterization of PEG-GO and Cellular Uptake GO was synthesized and functionalized with amine-terminated PEG (molecular weight of 5 kDa) according to our previous research (Yang et al., 2013) . A schematic illustration of the structure for PEG-GO is shown in Figure 1A . This modification allows PEG-GO with high water solubility and stability in physiological solutions including PBS and culture medium. PEG-GO were observed under the atomic force microscope (AFM) and showed small sizes of PEG-GO ranging from 10 to 50 nm with the mean size of 30 nm ( Figure 1B ). PEG-GO was mixed with tamoxifen, a CAD for prevention and treatment of breast cancer, and free drug was removed by filtration. To prove that the drug loaded PEG-GO are capable of entering the cells, human hepatoma HepG2 cells were incubated with PEG-GO loaded with tamoxifen (PEG-GO/tamoxifen) as mentioned above and imaged by Raman confocal microscopy. A significant amount of PEG-GO were attached to the cell membrane ( Figure 1C ), while cellular uptake of PEG-GO/tamoxifen was also observed in the cytoplasm, as shown by the characteristic D and G bands of graphene, indicating the PEG-GO endocytosis for drug delivery ( Figure 1D ).
Drug Loaded on PEG-GO Can Potentiate DIP To prove our hypothesis that CAD loaded on PEG-GO may potentiate DIP, PEG-GO/tamoxifen was studied for their ability to induce (PLD) compared with the tamoxifen treatment only. Tamoxifen at 64 lM was mixed with PEG-GO at 50 lg/ml in water for 12 h and the free drug was filtered by centrifugation and quantified by UV-vis. Our results revealed 94.7% loading efficiency and 90.1% loading capacity of tamoxifen on PEG-GO, indicating the high loading efficiency and capacity of PEG-GO on small molecules (Supplementary Table S1 ). Next, tamoxifen at 0, 2, and 8 lM were incubated with HepG2 cells for 48 h in 24-well plates. NBD-PE is a commonly used fluorescent phospholipid to quantify the intracellular phospholipid accumulation by CAD (Morelli et al., 2006; Ulrich et al., 1991) . There was a 4.5-fold increase (compared with non-treated control) of NBD-PE accumulation by tamoxifen at 8 lM through the quantification of intracellular fluorescence by flow cytometry, indicating the ability of tamoxifen to induce PLD (Figure 2A) . Strikingly, PEG-GO/tamoxifen further enhanced NBD-PE accumulation to 10.8-fold compared with control. To verify the results obtained from flow cytometry, cells were seeded on 96-well plates and cultured with tamoxifen or PEG-GO/tamoxifen at 0, 2, 4, 8, 16 lM, followed by high content screening to image the cellular accumulation of NBD-PE. As observed in Figure 2B , tamoxifen treated cells exhibited DIP in a dose dependent manner (top row of Figure 2B ), while PEG-GO/tamoxifen further enhanced DIP compared with the free drug (bottom row of Figure 2B ), which is in accordance with the flow cytometry data in Figure 2A .
The ultrastructural observation of multi-lamellar bodies is the hallmark of PLD. Therefore, transmission electron microscopy (TEM) was utilized to confirm if PEG-GO as the nanocarrier is able to potentiate DIP. Non-treated control or PEG-GO treatment showed an intact cell with a numerous of intracellular vacuoles, or lysosomes with the low electron density ( Figure  2C ). The presence of multicentric or unicentric lamellar inclusions (white arrows) were found in HepG2 treated with 8 lM tamoxifen for 48 h. In comparison, the cells treated with PEG-GO/tamoxifen revealed a significant increase in the number of lamellar bodies (white arrows) within the cells. To avoid the subjectivity of TEM, fifty cells were randomly selected from TEM images, and the total number of lamellar bodies for each type of treatment was counted. Total 97 lamellar bodies were found in fifty PEG-GO/tamoxifen treated cells, while only 60 were available in cells treated with tamoxifen alone (Supplementary Figure S1) .
Regulation of DIP Marker Genes by PEG-GO/Tamoxifen Treatment
Several studies have suggested a group of genes that can be used for diagnosis of PLD (Hirode et al., 2008; Nioi et al., 2007) . Therefore, we selected C10orf10, P8, INHBE, ASAH1, and FABP1 as up-regulated genes and SLC2A3 and TAGLN for downregulated genes that can be affected by CAD. To investigate if the drug loaded nanocarrier can further alter the gene expression regulated by the free drug, HepG2 cells were incubated with tamoxifen or PEG-GO/tamoxifen for 24 h. Total mRNA was extracted from cells and the marker genes were quantified by qRT-PCR. Other than C10orf10, the up-regulated genes showed a slight increase when tamoxifen was presented for 24 h, which is in accordance with Nioi's result (Nioi et al., 2007) . In comparison, when tamoxifen was loaded on PEG-GO and applied to HepG2 cells, a further increase of all the up-regulated genes was evident. Among the up-regulated marker genes, INHBE showed a 1.2-fold increase when cells were treated with tamoxifen only and was statistically different from non-treated control, while a 2.3-fold increase was found by PEG-GO/tamoxifen treatment. However, the down-regulated genes of SLC2A3 and TAGLN did not show any further decrease by PEG-GO/tamoxifen compared with the free drug (Figure 3 ).
Potentiation of DIP by PEG-GO Occurs over a Series of CAD in Different Cell Lines
The above results indicated that PEG-GO as the nanocarrier can potentiate tamoxifen induced PLD. However, it is not clear if the potentiation of DIP by the nanocarrier is specific only to tamoxifen, or is universal to other CAD. Amiodarone is an antiarrhythmic agent and is a classical CAD that has been reported to be a potent inducer of PLD (Atiq et al., 2009; Reasor, 1989) . Similar as tamoxifen, amiodarone loaded on PEG-GO significantly increased PLD (9.5-fold) compared with amiodarone alone (5-fold increase) using flow cytometry that can be confirmed by high content imaging system (Supplementary Figure S2) .
Over 50 marketed drugs have been capable of DIP during the past 40 years (Reasor and Kacew, 2001 ; Shayman and Abe, 2013).
Other than tamoxifen and amiodarone, alternative CAD such as ketoconazole, amitriptyline, chlorpromazine, fluoxetine as classical PLD inducers were selected, aiming to investigate if PEG-GO as the nanocarrier can potentiate DIP by different drugs. First, MTT assay was used to evaluate the cytotoxicity of each drug (Supplementary Figure S3) , making sure that the DIP studies were all performed at non-toxic or low toxic concentrations of drugs. As a result, all 6 drugs with concentrations smaller than 16 lM were selected for drug loading on PEG-GO. Alternatively, we also conducted the loading efficiency and capacity of PEG-GO on all 6 drugs. The chemical structures of all six CAD were illustrated in Supplementary Table S1 . Water soluble CAD (at 64 lg/ml) such as amitriptyline, chlorpromazine and fluoxetine have loading efficiency at 39.3, 50.7, and 44.8%, respectively, while DMSO soluble drugs tamoxifen, amiodarone and ketoconazole are much higher at 94.7, 98.7, and 60.8% (Supplementary Table S1 ). The results showed efficient drug FIG. 1. Chemical characterization of PEG-GO and the cellular uptake. A, Schematic illustration of the PEG-GO structure. B, AFM images of PEG-GO. C, Intracellular PEG-GO by confocal Raman imaging. PEG-GO at 50 lg/ml and tamoxifen at 16 lM were mixed for 12 h and the free drug was removed through filtration. HepG2 were treated with PEG-GO/tamoxifen for 48 h and imaged by Raman spectra mapping. The red false color in the cell indicated the localization of PEG-GO. Location 1 is in the cytoplasm while location 2 is out of the cell. D, Raman spectrum obtained from the above 2 locations were acquired, showing the typical D and G bands of graphene in location 1.
FIG. 2. PLD induced by tamoxifen was further potentiated by drug loading on PEG-GO.
A, PLD fluorescence in the cells with mean value quantified by flow cytometry. HepG2 were treated with tamoxifen at final concentrations of 0, 2, and 8 lM or PEG-GO/tamoxifen at corresponding tamoxifen concentrations for 48 h in the presence of NBD-PE. Cells were collected and quantified with NBD-PE fluorescence by flow cytometry. The PLD induction difference between tamoxifen and PEG-GO/tamoxifen was evaluated by student t-test (***P < .001). B, Representative images for green fluorescence in the cells imaged by high content screening system. HepG2 were treated with tamoxifen at 0, 2, 4, 8, and 16 lM or PEG-GO/tamoxifen at corresponding tamoxifen concentrations for 48 h in the presence of NBD-PE and imaged by the high content imaging system. C, Transmission electron micrographs of PLD induction. HepG2 cells were treated with medium alone, PEG-GO, tamoxifen, or PEG-GO/tamoxifen for 48 h and imaged by TEM. White arrows indicate the localization of lamellar bodies in the cells.
loading efficiency and capacity of PEG-GO (finally concentration at 25 lg/ml), which depends on the physicochemical characteristics of each individual drug.
In general, DIP was not only found in hepatocytes, but also in Kupffer cells or other types of macrophages during the time of drug therapy. In our extended studies, 2 cell lines including HepG2 and Raw264.7 (a mouse macrophage cell line) were selected for the evaluation of PLD in vitro. Cells were all subjected to PEG-GO/CAD for 48 h. By using the high content screening method, all 6 free CAD were capable of inducing PLD in a dose dependent manner in both cell lines (Figure 4) . Interestingly, PEG-GO loaded with tamoxifen, amiodarone, or ketoconazole revealed significant increases in DIP compared with free drugs alone in both Raw264.7 and HepG2 cell lines (Figs. 4A and B) , while PEG-GO loaded with amitriptyline, chlorpromazine, or fluoxetine showed less extent of potentiation effect on DIP compared with free drugs, indicating that the potentiation of PEG-GO on DIP may correlate with the drug binding on PEG-GO. In summary, the above studies showed that the potentiation of DIP by the nanocarrier is common for some CAD, which is likely dependent upon the drug loading capacity of the nanocarrier. In addition, the potentiation effects and strength by nanocarrier/CAD also highly depends on cell types.
PEG-GO/Tamoxifen Showed a Delayed but Potent Induction of DIP
To reveal the detailed process of PLD induced by free CAD or PEG-GO/CAD, a PLD kinetic study from 6 to 48 h (with 6-h interval) were performed. HepG2 were incubated with tamoxifen or PEG-GO/tamoxifen and collected at certain time points as mentioned earlier, and NBD-PE fluorescence in the cells was quantified by flow cytometry. We found a rapid increase of the intracellular phospholipid accumulation by tamoxifen within 24 h, while a relatively slow PLD response was found for PEG-GO/tamoxifen that came up to the same value as the free tamoxifen at 24 h ( Figure 5A ). Tamoxifen-induced PLD reached a plateau after 24 h, while PEG-GO/tamoxifen treated cells exhibited a continued PLD induction until 48 h. Similar delayed induction of DIP by PEG-GO was evident for amiodarone (Supplementary Figure S4A) . The above experiments revealed a delayed but robust increase of DIP at later time points from 24 to 48 h when CAD were loaded on PEG-GO.
PEG-GO/Tamoxifen Showed a Slow Recovery of DIP when Drug was
Removed DIP is reversible and the intracellular phospholipid may return to the normal level after the clinical discontinuance of the drug (McCloud et al., 1995; Reasor and Walker, 1981) . To investigate the differentiated reversibility of PLD induced by free CAD or PEG-GO/CAD, we studied the in vitro "elimination" phase of DIP by the removal of the drug or drug loaded nanocarrier. Cells were first incubated with tamoxifen or PEG-GO/tamoxifen for 48 h for induction of PLD (as indicated in Figure 5A ), then the inducing reagents were removed for PLD recovery. During another 48 h recovery period, tamoxifen treated cells exhibited a complete reduction of PLD at the end of 48 h, while PEG-GO/ tamoxifen retained some residual phospholipid accumulation ( Figure 5B ). We also conducted the recovery experiments for amiodarone. Similarly, PEG-GO/amiodarone-induced PLD did not recover as rapidly as amiodarone alone (Supplementary Figure S4B) . These results provide strong evidence that the nanocarrier may significantly delay the recovery of DIP after discontinuing the therapeutic drugs.
Co-Localization between NBD-PE and Lysosomes during PEG-GO Potentiation on DIP
A typical feature of PLD is the appearance of lamellar bodies as observed by TEM ( Figure 2C ). The lamellar bodies are specific organelles as a subclass of lysosomes. Therefore, we investigated if NBD-PE accumulation had any correlation with lysosomes. As expected, PEG-GO/tamoxifen treated cells showed a greater NBD-PE accumulation compared with the tamoxifen only (first column of Figure 6A ). Tamoxifen significantly increased the amount of lysosomes compared with the nontreated control, while PEG-GO/tamoxifen further enhanced this effect, implying the generation of more lamellar bodies by the drug loaded nanocarrier than drug only (second column of Figure 6A ). In addition, we observed more co-localization between NBD-PE and lysosomes in PEG-GO/tamoxifen treated cells than tamoxifen only, providing the possibility that PEG-GO may further facilitate drug accumulation in the lysosomes than free drug (fourth column of Figure 6A ).
LAMP2 was identified as the protein marker for PLD in vitro and in vivo (Hariri et al., 2000; Obert et al., 2007) . We investigated if PEG-GO can further altered the LAMP2 expression induced by and PEG-GO/CAD was evaluated by student t-test (*.01 < P < .05,**.01 < P < .001, and ***P < .001).
tamoxifen. LAMP2 expression was increased in tamoxifen treated cells (second column of Figure 6B ). Similar as LysoTracker staining, we found a slightly further increase of LAMP2 expression induced by PEG-GO/tamoxifen compared with tamoxifen alone. In addition, more co-localization between NBD-PE and LAMP2 in PEG-GO/tamoxifen than the tamoxifen treated sample was revealed (fourth column of Figure 6B ). All of the above results clearly indicate that the PEG-GO/tamoxifen can strongly induce more severe PLD compared with the free drug, most likely due to the increase in drug accumulation within the lysosomes.
PEG-GO and DIP May not Be Correlated with Autophagy
It has been speculated that the formation of lamellar bodies, the hallmark of PLD may occur through autophagy, and studies showed that these lamellar bodies are able to fuse with autophagosomes (Schmitz and Mü ller, 1991; Weaver et al., 2002) . To verify their observation, we first investigated if PEG-GO (as the nanocarrier), or tamoxifen, or PEO-GO/tamoxifen can induce autophagy. As indicated in Figure 7A , autophagy marker LC3I/II was stimulated by PEG-GO in a dose dependent manner. In addition, an increase in LC3I/II was also revealed by tamoxifen alone, while a further increase of autophagy in PEG-GO/ tamoxifen treated sample was evident ( Figure 7B ). As an autophagy inhibitor, 3-MA was able to inhibit tamoxifen or PEG-GO induced autophagy indicated by the reduction in LC3I/II expression ( Figure 7C ). However, 3-MA with concentrations ranging from 0.25 to 1 mM all failed to reduce PEG-GO, tamoxifen or PEG-GO/Tamoxifen-induced PLD performed by the high content screening system and image analysis ( Figure 7D ). Finally, NBD-PE accumulation by tamoxifen or PEG-GO/ tamoxifen did not show any co-localization with LC3 ( Figure  7E ). All these results suggested that PEG-GO and tamoxifeninduced PLD was not associated with the autophagic mechanisms ( Figure 7D ).
DISCUSSION
DIP has been considered as one of the major concerns during drug development. Through the observation of TEM micrographs, phospholipid accumulation in the cells was evident with the appearance of concentric myelin-like inclusions, or lamellar bodies as observed from Figure 2C . Although DIP is open to debate due to its uncertainty for toxicity, regulatory agencies such as U.S. FDA classified DIP as an adverse drug effect. If DIP occurs during drug development, it may significantly delay the drug approval. In addition, FDA has built a database containing over 700 DIP positive and negative drugs and developed quantitative structure-activity relationship models, aiming to correlate and predict DIP based on the chemical structures of the drugs (Choi et al., 2013; Kruhlak et al., 2008; Orogo et al., 2012; Slavov et al., 2014) . Therefore, abnormal drug accumulation could be harmful to human health. In recent years, nanocarriers for drug delivery have been widely recognized by researchers due to their controlled drug release and target specificity (Hsu et al., 2016; Zhang et al., 2010) . Although toxic residue removal have been performed during the production of nanocarriers aiming to minimize their inherent toxicity, fixed at an interval of 6 h until 48 h. The intracellular NBD-PE mean fluorescence indicative of the severity of PLD was measured by flow cytometry. The value from the tamoxifen sample and PEG-GO/tamoxifen samples were compared each other for each time point by student t-test (**P < .01). B, After induction of PLD at 48 h, tamoxifen or/and PEG-GO were removed, and live cells were stained with Hoechst 33258. The intracellular NBD-PE fluorescence were continued to be recorded with an interval of 6 h for another 48 h by high content imaging system, and quantified through MetaXpresss software.
the long term accumulation of the nanocarrier in the cells or tissues is inevitable, especially for inorganic nanomaterials. Our current concerns focus on the intracellular drug accumulation that could be further retained by the nanocarrier. If the small molecule has certain adverse effects, would its retention in the cells by the nanocarrier exacerbate the adverse drug effect in the long-term?
In our studies, PEG-GO was used as a model nanocarrier, which was shown to have a high loading capacity through p-p stacking or hydrophobic interactions. It was reported from Yang et al. (2010) revealed a 200% loading capacity of GO for doxorubicin. Our studies showed the loading capacity of CAD was highly dependent upon the solubility characteristics of the drugs. Based on Supplementary Table S1 , it is demonstrated A, Cells were stained with Lysotracker (red) followed by Hoechst dye (blue). B, Cells were stained with anti-LAMP2/Alexa Fluor 568 (red) and Hoechst dye. Stained cells were imaged by confocal laser scanning microscopy (CLSM).
FIG. 7.
PEG-GO/tamoxifen-induced PLD and autophagy are independent from each other. HepG2 were treated with PEG-GO (A), tamoxifen or PEG-GO/tamoxifen (B) for 48 h for the induction of autophagy. The expression of LC3I/II was evaluated by western blot. C, PEG-GO/tamoxifen-induced autophagy can be inhibited by 3-MA.
HepG2 cells treated with tamoxifen alone or PEG-GO in the absence or presence of 3-MA, a specific inhibitor of autophagy. GAPDH is the internal control. D, Autophagy inhibitor 3-MA had no influence on PEG-GO or/and tamoxifen-induced PLD. HepG2 were treated with PEG, tamoxifen or PEG-GO/tamoxifen accompanied with different concentrations of 3-MA for 48 h. The cell fluorescence was evaluated by high content imaging according to materials and methods. E, NBD-PE had no co-localization with LC3. HepG2 cells were treated with tamoxifen at 8 lM or PEG-GO/tamoxifen in the presence of NBD-PE (green). Cells were stained with anti-LC3/Alexa Fluor 568 (red) and Hoechst dye (blue) and imaged by CLSM.
that water soluble CAD such as amytriptyline, chlorpromazine and fluoxetine have relatively much lower loading efficiency and capacity than DMSO soluble CAD. Therefore, we especially wanted to address if these 2 types of CAD have differential DIP potentiation when loaded on PEG-GO. We initiated our study by using tamoxifen for breast cancer treatment and chemoprevention for over forty years (Nazarali and Narod, 2014) . Through flow cytometry, high content imaging system and TEM, it was evident that PEG-GO/tamoxifen introduced more severe PLD than the free drug (Figure 2) . Actually, not only tamoxifen but some of the other CAD have showed similar DIP potentiation effects in 2 different cell types (Figure 4) . The selected CAD include antidepressants, antianginal, antimalarial, and cholesterol-lowering agents, which are widely used in different therapeutic fields for decades. Our results indicated that the DIP potentiation by drug loaded nanocarrier may strongly depend on the physicochemical properties of the individual drug and the nanocarrier, nanocarrier loading efficiency and capacity of the drug, the cellular uptake efficiency of nanocarriers, all of which may contribute to the severity of DIP potentiated by the drug loaded nanocarrier.
Several investigators have screened from DNA microarray and selected more than a dozen of genes as the marker genes for DIP (Nioi et al., 2007; Sawada et al., 2005) . Based on their results, we chose 5 up-regulated genes and 2 down-regulated genes by classical CAD (PLD inducers). As shown in Figure 3 , it is noted that 2 genes such as P8 and INHBE were further upregulated by PEG-GO/tamoxifen compared with tamoxifen alone. Studies showed that ceramide can cause the induction of p8, resulting in cell apoptosis (Carracedo et al., 2006) . Recent studies showed that this transcription factor may play an important role in autophagy regulation Lin et al., 2016) . In comparison, INHBE is a stress response gene and can suppress cell growth. The further up-regulation of p8 and INHBE by tamoxifen loaded on PEG-GO indicated that the nanocarrier may bring forward a status of autophagy, apoptosis or cell growth inhibition, and that the nanocarrier for drug delivery may bring more severe adverse drug effects than the free drugs.
The most commonly used time point for toxicology studies is 24 h. Therefore, at the beginning of our study, we investigated if DIP could be enhanced through the nanocarrier at 24 h. However, we had difficulty to find any further increase of PLD in PEG-GO/tamoxifen sample compared with free tamoxifen treatment. The results were, we suspected, likely attributed from a relatively short treatment period of PEG-GO/tamoxifen on HepG2. Therefore, we extended the drug incubation time to 48 h and found the potentiation effect of PEG-GO on DIP as indicated in Figure 2 . Through kinetic studies, we proved a stronger PLD Scheme 1. Nanocarrier may potentiate DIP. In this model, PEG-GO is the nanocarrier, while tamoxifen is a classical CAD that can develop PLD. In the absence of CAD and nanocarrier, lysosomes contain a physiological level of phospholipids (A). CAD can introduce PLD leading to NBD-PE (a fluorescent phospholipid, green) accumulation in the lamellar bodies marked by LAMP2 (red) that can be co-localized with NBD-PE (yellow); when CAD is removed from the cell culture (or through the discontinuance of drug from the patient), PLD is usually reversible over time with the decreased number of phospholipid and lamellar bodies (B). When CAD is loaded on the nanocarrier, CAD can be trapped or released slowly by the indigestible nanocarrier, resulting in a delayed but potent effect of PLD, shown as the further increase in NBD-PE and LAMP2 as well as their co-localization pattern, indicating strong accumulation of phospholipid in the lysosomes; when CAD/nanocarrier are removed, the reversibility of PLD could be significantly retarded and may become irreversible, a sign of drug accumulation and adverse drug effect in the long term (C).
effect by PEG-GO/tamoxifen with a delayed induction phase compared with tamoxifen only, which induced a quick PLD induction within 24 h but seemed to lack potential after 24 h ( Figure 5A ). It is very likely that tamoxifen can enter cells via passive diffusion and accumulate in the lysosome quickly to exert its DIP effect. In comparison, PEG-GO/tamoxifen may enter the cells through endocytosis, which requires ATP and protein transporters/adaptors with slower permeabilization rate than free drugs. In addition, PEG-GO may introduce the slow release of tamoxifen (or other drugs) in the lysosomes (Supplementary Figure S5) , in which the tamoxifen can interact with phospholipases followed by inhibition of enzyme activity, resulting in intracellular phospholipid accumulation. Therefore, both endocytosis of nanocarrier and intra-lysosomal release of the loaded drug both determined the delayed effects of PLD induced by drug loaded nanocarrier.
When the clinical drug was discontinued, reversibility is the typical feature of DIP, indicating the drug removal from the cytoplasm with time. What if the drug is loaded on or in the nanocarrier? As shown in Figure 5B , the retarded reversibility of PLD after replacement of PEG-GO/tamoxifen with fresh culture medium was likely attributed from the slow drug elimination trapped by the nanocarrier in the lysosomes. Actually, we noted more lysosomal co-localization with NBD-PE by PEG-GO/ tamoxifen than tamoxifen only (Figure 6 ), providing the fact that phospholipid accumulation accompanied with drug retention by PEG-GO was evident at a higher level than the free drugs in the lysosomes or lamellar bodies. In addition, the introduction of an excess amount of lysosomes by PEG-GO/tamoxifen may render the cells in a sub-toxic environment. It was reported that some NP can lower lysosomal pH through re-acidification process (Bourdenx et al., 2016) . Therefore PEG-GO loaded with CAD could play a role in the increased amount of lysosomes that can potentially further inhibit the drug removal from cytoplasm trapped by the nanocarrier.
Although DIP does not necessarily develop toxicity, phospholipid accumulation in the lysosomes where the drugs were trapped by the nanocarrier indicates that the mechanisms for nanocarrier/CAD enhanced PLD could be more complex than expected. In recent years, it was suspected that autophagy may link with DIP and lysosomal lipid storage disorders (Buratta et al., 2015) . In addition, it was reported that multi-lamellar bodies were generated via autophagy (Hariri et al., 2000) . Although we found the autophagy induction by PEG-GO/ tamoxifen that can be inhibited by the autophagy inhibitor (3-MA), we did not find that 3-MA was capable of preventing PLD induced by PEG-GO/tamoxifen (Figure 7) . The discrepancy between our results and the work from other groups, along with the absence of co-localization between NBD-PE and LC3, has provided the evidence that nanocarrier/CAD induced PLD may not be correlated with autophagy. Lamellar bodies can function as specialized organelles for content storage and secretion, while regular lysosomes are usually for content degradation (Weaver et al., 2002) . Therefore, other mechanisms regarding the potential secretion of lamellar bodies to remove excess phospholipids by the nanocarrier/CAD may be interesting to be elucidated in the future.
Overall, our studies are of importance and are critical for drug development in the pharmaceutical industries. These findings may also influence the decision by regulatory authorities on investigational new drug applications related to the use of nanotechnology for drug delivery. Currently, only a few nanodrugs are FDA approved for cancer therapy, such as PEGylated doxorubicin-loaded liposomes and paclitaxel bound to albumin NP, both of which can overcome the insolubility of the drugs (Desai et al., 2006; Gabizon, 2001) . FDA has only issued 3 final guidance documents for the use of nanotechnology in cosmetics, food substances, and food for animals. In comparison, no regulatory guidance has been published and enforced for nanotechnology in drug products. Therefore, the uncertainty and regulatory concerns for application of nanocarriers in drug delivery remains. When seen from a bigger picture, nanocarriers for drug delivery may induce further drug accumulation in the human body; therefore, the adverse drug effect could be exaggerated by nanocarriers that can further trap the drugs in the lysosomes. Therefore, with the use of nanotechnology for drug development, new strategies, amendments and notices should be discussed and proposed by regulatory agencies that nanotechnology may create severe adverse drug effects. Also, our conclusion alerts the pharmaceutical companies to be cautious about the use of nanocarrier during drug development. Additional studies for long term drug accumulation by the nanocarrier with associated toxicity need to be conducted to further understand the severity of the nanocarrier potentiated adverse drug effect in vitro and in vivo.
CONCLUSIONS
In summary, our results have reported for the first time that nanocarriers may potentiate DIP with a delayed but stronger effect than free CAD (PLD inducers), as summarized in Scheme 1. In addition, nanocarrier for CAD delivery may further retain the phospholipid and drug accumulation in the cells for longer time, and can change the reversibility of DIP to a more persistent syndrome, resulting in chronic toxicity due to the longterm drug retention in the lysosomes of normal human cells. Although more experiments need to be conducted to further verify our results, nanocarrier potentiated DIP may depend upon the type of the nanocarrier, the physicochemical properties of the small molecule drugs, phagocytic capacity of cells and duration of treatment.
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